Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
about
Microtubule-binding agents: a dynamic field of cancer therapeutics.Ixabepilone for the treatment of solid tumors: a review of clinical dataPhase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology GroupIxabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsQuantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomasThe epothilones: new therapeutic agents for castration-resistant prostate cancer.Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBortezomib in mantle cell lymphoma.Ixabepilone for the treatment of taxane-refractory breast cancer.Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Epothilones in breast cancer: current status and future directions.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancerIxabepilone as monotherapy or in combination for the treatment of advanced breast cancer.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Ixabepilone: a new active chemotherapy in the treatment of breast cancer.The epothilones: how pharmacology relates to clinical utility.Dose-toxicity models in oncology.Epothilones in the treatment of ovarian cancer.Global experience with ixabepilone in breast cancer.Ixabepilone for the treatment of breast cancer.Ixabepilone for the treatment of endometrial cancer.Azaepothilone B and its derivatives: a patent review.Macrolactam analogues of macrolide natural products.Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease
P2860
Q27690249-C53F5FB6-BCD0-49BC-90D2-EC4954180ACBQ28271570-888A3C9A-F409-48A6-8EC1-2DCB53CBBFE4Q30433670-3C188286-4FDA-45C7-9AB1-EF7249DFCC17Q33380465-7DC6E1F4-F001-4574-9F66-6B9CA4AC0A2AQ33400047-99424421-389B-4016-AD60-F10CD2E460A2Q34180965-A71346F8-1764-4C95-BB5A-3811709BCEF9Q34266295-98525308-CE81-4561-851A-CE1FD1A7E968Q34611212-82B79F8F-94CC-402A-8DD4-9217453C6773Q34611801-716BC302-E1C8-4F08-BE6B-3EE18ED7C4F7Q34788890-07777B4D-CAAC-4F8F-B074-40AA8BE51882Q35096335-8860E03E-1249-4EBD-9C81-999713A5D1BAQ35584399-9449378B-4888-4450-8192-7BD057E07E6FQ35884220-AD66D798-F2C5-4FE2-9FD9-CF3733CC7B9BQ35997562-E518B873-390F-43B7-BBF6-8D8E75ECDB2BQ36714374-D85B3925-8200-412C-8EBD-7949C389043AQ36988082-C568B4DD-A759-4C83-851E-E7B053E9C365Q37104791-D86DBF33-6514-4928-A854-6E9A4EE631DBQ37136989-C24DC04E-F592-42B1-8352-A24007AAC8D8Q37179381-B64DB734-76AA-4F93-B1CC-91B110BFF1FFQ37236419-74A65EB2-C107-4DB4-9481-93B5689C4D4CQ37242676-CB6D2172-4CE3-41FE-8585-45DFF0C4B5A7Q37262792-4BDA1F88-BD11-4BB4-AA62-B63899143166Q37290709-3842187A-449F-4BBD-8020-D5A1CED074DAQ37356274-57A1514F-6770-422E-8AF2-7A68B78E3936Q37378233-AB934E66-C6B1-45D7-95C3-3D010C97443BQ37401833-787E2DB3-FB3D-4D8C-99F4-23D2576EFAF0Q37543912-7767F7B6-D1CD-4736-932D-7D01E4CBA5D5Q37829437-8F8AF18B-DF09-483A-8C63-26BD7E53199AQ37861204-A1701D6E-FEFF-4891-911B-1A6CE015D218Q37873462-960A9E35-5472-48B0-B146-5A7046C91CB3Q37876407-8D799227-4306-404E-B32E-8F1487BB309BQ38763500-80811AF7-4610-41ED-B12E-C45076658052Q38860410-2E9F8E01-B19F-43D5-917A-04BB66FBED92Q38998257-F75AF409-8BB4-4381-8A49-15D282A07567Q47568290-F7615374-25D2-49C1-B3F1-F2CBD8A624CEQ49787954-4E27726E-24A4-46D5-B70A-25F4124EC603Q57244875-CEEC9E71-68B1-4360-BC28-E85C120A44F1
P2860
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@ast
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@en
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@nl
type
label
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@ast
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@en
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@nl
prefLabel
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@ast
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@en
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@nl
P2093
P356
P1476
Phase I study of the novel epo ...... ced solid tumors and lymphomas
@en
P2093
Carol Aghajanian
David R Spriggs
F Anthony Greco
Howard A Burris
Jakob Dupont
Martee L Hensley
Marvin B Cohen
Owen A O'Connor
Paul Sabbatini
Ronald Peck
P304
P356
10.1200/JCO.2006.08.7304
P407
P577
2007-03-20T00:00:00Z